Preventing microalbuminuria in patients with type 2 diabetes (Q36648858)

15 August 2017

1 reference

title

Preventing microalbuminuria in patients with type 2 diabetes (English)

1 reference

15 August 2017

1 reference

György Jermendy

1

1 reference

PubMed ID

17094161

15 August 2017

Piero Ruggenenti

series ordinal

2

1 reference

15 August 2017

1 February 2007

1 reference

Diabetes - Metabolism: Research and Reviews

15 August 2017

1 reference

15 August 2017

23

1 reference

15 August 2017

2

1 reference

15 August 2017

100-110

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

15 August 2017

1 reference

Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction

21 January 2018

1 reference

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

21 January 2018

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

7 January 2021

Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop

1 reference

7 January 2021

Lifetime Risk for Diabetes Mellitus in the United States

1 reference

7 January 2021

Direct medical costs of complications resulting from type 2 diabetes in the U.S.

1 reference

7 January 2021

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S

1 reference

7 January 2021

Assessing the impact of complications on the costs of Type II diabetes.

1 reference

7 January 2021

Diabetic nephropathy in type II diabetes

1 reference

7 January 2021

Nephropathy in patients with type 2 diabetes mellitus

1 reference

7 January 2021

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions

1 reference

7 January 2021

Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?

1 reference

7 January 2021

Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes

1 reference

7 January 2021

Microalbuminuria as an early marker for cardiovascular disease

1 reference

7 January 2021

Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria

1 reference

7 January 2021

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

1 reference

7 January 2021

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

7 January 2021

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults

1 reference

7 January 2021

Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes

1 reference

7 January 2021

New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death

1 reference

7 January 2021

'Hypertension' and 'microalbuminuria': the bell tolls for thee

1 reference

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

7 January 2021

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

7 January 2021

Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study

1 reference

7 January 2021

Clinical practice. Nephropathy in patients with type 2 diabetes

1 reference

7 January 2021

The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus

1 reference

7 January 2021

Variability of urinary albumin excretion in patients with microalbuminuria

1 reference

7 January 2021

Microalbuminuria predicts mortality in non-insulin-dependent diabetics

1 reference

7 January 2021

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

1 reference

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

7 January 2021

Albuminuria reflects widespread vascular damage. The Steno hypothesis.

1 reference

7 January 2021

Vascular complications in diabetes mellitus: the role of endothelial dysfunction

1 reference

7 January 2021

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

1 reference

7 January 2021

Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study

1 reference

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

7 January 2021

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 reference

7 January 2021

Diabetic nephropathy: prevention and treatment

1 reference

7 January 2021

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

7 January 2021

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients

1 reference

7 January 2021

Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

1 reference

7 January 2021

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

1 reference

7 January 2021

Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics

1 reference

7 January 2021

The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics

1 reference

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

7 January 2021

Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes

1 reference

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

7 January 2021

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

1 reference

7 January 2021

Antihypertensive agents for primary prevention of diabetic nephropathy

1 reference

7 January 2021

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

1 reference

7 January 2021

Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes.

1 reference

7 January 2021

Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes--data from the National Diabetes Register in Sweden

1 reference

7 January 2021

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

1 reference

7 January 2021

Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment

1 reference

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

7 January 2021

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study

1 reference

7 January 2021

Statins for improving renal outcomes: a meta-analysis

1 reference

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

7 January 2021

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

7 January 2021

Managing anaemia and diabetes: a future challenge for nephrologists

1 reference

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

7 January 2021

Diabetic nephropathy: diagnosis, prevention, and treatment

1 reference

7 January 2021

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

1 reference

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

7 January 2021

Proteinuria in diabetic nephropathy: treatment and evolution

1 reference

7 January 2021

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

1 reference

7 January 2021

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

1 reference

7 January 2021

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

1 reference

7 January 2021

The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes

1 reference

7 January 2021

Renoprotection: a matter of blood pressure reduction or agent-characteristics?

1 reference

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

7 January 2021

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

1 reference

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

7 January 2021

Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.693

1 reference

15 August 2017

1 reference

PubMed ID

17094161